S

Soligenix
D

SNGX

2.42600
USD
-0.02
(-0.98%)
مغلق
حجم التداول
1,188
الربح لكل سهم
-3
العائد الربحي
-
P/E
-0
حجم السوق
6,088,045
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALT
    -0.19000
    (-2.87%)
    6.42000 USD
    I
    INO
    0.02000
    (0.91%)
    2.23000 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    N
    NVAX
    0.05500
    (0.69%)
    7.98000 USD
    S
    SNES
    -0.19000
    (-5.94%)
    3.01000 USD
    V
    VXRT
    0.00670
    (0.95%)
    0.70980 USD
    المزيد
الأخبار
المقالات

العنوان: Soligenix Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).